Tenapanor Hydrochloride

Ardelyx is running a new ad campaign for its irritable bowel syndrome with constipation (IBS-C) drug, Ibsrela, across connected TV. The 60-second spot zeroes in on the “Because Ibsrela Can” catchphrase and follows a young woman out in the woods with her friends enjoying the scenery. It also comes with a heavy amount of data from trials on how the drug can help reduce bloating and pain while increasing bowel movements, as well as information on side effects. The data moves to the forefront of the screen as the narrator spells it out. A company spokesperson told Fierce the commercial is projected to reach around 10 million to 17 million viewers across streaming platforms, including Netflix, Hulu, Prime Video, Peacock and others. The campaign also uses patient education materials, digital banner advertising, audio placements, paid search, CRM communications and a People magazine cover wrap distributed to healthcare providers. “The ‘Because Ibsrela Can’ campaign was inspired by the experiences and perspectives of people living with IBS-C and reflects insights gathered directly from the patient community,” said Jami Giordano, senior vice president and general manager at Ardelyx, in a statement to Fierce. “By bringing these patient stories to life through a broad, multi-channel campaign, we hope to highlight the experiences of people living with IBS-C and the moments that matter to them, while encouraging informed conversations with their healthcare providers.” Ibsrela, an NHE3 inhibitor, scored its first green light to treat irritable bowel syndrome with constipation in September 2019. But the commercial launch was delayed by around three years as Ardelyx struggled to gain a second approval for the drug in kidney disease. It eventually secured that FDA approval after a long and difficult road, with the drug sold under a different brand name for the kidney disease indication. Ibsrela saw its revenue grow 73% in 2025 to reach $274.2 million.